These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33061865)

  • 21. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 22. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
    Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Braeckman RA; Philip S; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2016; 10(3):635-645.e1. PubMed ID: 27206952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text.
    Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG
    Curr Vasc Pharmacol; 2019; 17(5):498-514. PubMed ID: 31060488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction.
    Mason RP; Eckel RH
    Am J Med; 2021 Sep; 134(9):1085-1090. PubMed ID: 33864765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Icosapent Ethyl: Niche Drug or for the Masses?
    Bazarbashi N; Miller M
    Curr Cardiol Rep; 2020 Aug; 22(10):104. PubMed ID: 32770402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
    Lakshmanan S; Budoff MJ
    Heart Int; 2021; 15(1):7-13. PubMed ID: 36277323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ
    Eur Heart J Cardiovasc Pharmacother; 2024 Apr; ():. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
    Maki KC; Dicklin MR
    Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
    Miller M; Bhatt DL; Brinton EA; Jacobson TA; Steg PG; Pineda AL; Ketchum SB; Doyle RT; Tardif JC; Ballantyne CM
    Eur Heart J Open; 2023 Nov; 3(6):oead114. PubMed ID: 38035037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is really new in triglyceride guidelines?
    Hussain A; Al Rifai M; Hermel M; Slipczuk L; Virani SS
    Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):73-80. PubMed ID: 36722448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study.
    Madsen CM; Varbo A; Nordestgaard BG
    Eur Heart J; 2018 Feb; 39(7):610-619. PubMed ID: 29182745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.